SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after a patent infringement lawsuit from Novo Nordisk and FDA scrutiny led the company to halt its oral semaglutide pill offering. The community is sharply divided, with many fearing bankruptcy and further declines due to regulatory and legal challenges, while others view it as an oversold "short squeeze" candidate given its strong core business.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is trending as its S-4 registration for the Infleqtion merger is effective, setting a February 12 shareholder vote and a ticker change to INFQ by February 17. The community is buzzing about Infleqtion's quantum technology, new contracts with NASA and the Department of Energy, and its perceived undervaluation compared to quantum peers, with many anticipating a significant post-merger rally.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab (SCHW) is trending as the broader financial advisory sector reacts to fears that a new AI tax strategy tool from Altruist could disrupt traditional wealth management services and compress fees. The community is debating if this selloff is an overreaction or a legitimate threat, with many viewing it as a "buy the dip" opportunity for established firms to quickly adapt.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune (EVMN) is experiencing a sharp rally driven by positive Phase 2a trial results for its atopic dermatitis drug, EVO301, which met its primary efficacy endpoint. The positive data has led to significant analyst price target raises, sparking widespread community discussion around its upside potential and short squeeze dynamics.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify (SPOT) is surging after reporting a blockbuster Q4, driven by record user growth, increased premium subscribers, and improved profitability, fueling widespread bullish sentiment and discussions of a potential short squeeze.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors celebrate its announced Q4 profitability and reiteration of a 2026 annual profit target, alongside reaching 100 million battery swaps. Despite a minor software recall and a perceived manipulative analyst downgrade, the community is buzzing with anticipation of a significant short squeeze, believing the stock is deeply undervalued given its improving fundamentals and unique battery-swapping technology.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is seeing significant volatility after its Q4 earnings report, which revealed a revenue miss and conservative guidance despite overall profitability, sparking a heated debate among investors. While many believe the stock's sharp decline is an overreaction driven by market manipulation and short interest, others express deep frustration over its continued downward trend amidst broader fintech sector weakness.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after Morgan Stanley initiated coverage with an "Overweight" rating and a $37 price target, emphasizing the company's strong position in transitioning from Bitcoin mining to AI data centers. The community is buzzing with speculation about imminent hyperscaler deals and the potential for a significant short squeeze, anticipating further price breakouts.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending after its Q4 report showed strong revenue and GMV growth with significantly reduced losses, setting a clear path to profitability. The community is actively debating a "sell the news" reaction despite strong fundamentals and increasing analyst optimism for the "Amazon of Africa" narrative.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is seeing a significant downturn in its stock as the Centers for Medicare & Medicaid Services proposed near-flat Medicare Advantage payment rates for 2027, below market expectations. This has led to substantial selling pressure and the stock trading at multi-year lows, with some in the community viewing the dip as an attractive buying opportunity while others express concern over the company's high reliance on MA.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 7.8% Higher - Here's Why

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 7.8% - What's Next...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3% - Here's What Happened

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3% - Should You Sell...

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned a consensus rating of "Buy" from the seven brokerages that are currently covering the stock, MarketBeat reports...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Time to Buy?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - What's Next...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.6% - Here's Why

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 4.6% - What's Next...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1% - Here's What Happened

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.1% - Here's Why...

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has received a consensus recommendation of "Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports...

127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC

Corient Private Wealth LLC bought a new stake in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2% - Time to Sell?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2% - What's Next...

EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know 

Does EyePoint (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Current Price	$13.59
Prev Close	$14.07
Open	$14.10
Dividend Yield	0.00%
50-Day Moving Average	$15.99
Beta	1.26
Avg. Volume	951,267.80
PE Ratio	-4.71

52-Week High	$19.11
52-Week Low	$3.91
Market Capitalization	$1.16B
EPS (Annual)	-$2.32
Price to Book	4.89
Revenue Per Employee	$262,260.61
Enterprise Value/EBITDA	N/A

EYPT
EyePoint Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EYPT News

EYPTEyePoint Pharmaceuticals Inc